Mira Pharmaceuticals, Inc. completed its Phase 1 dosing of Ketamir-2 on March 3, 2026, which showed no serious adverse effects in 56 healthy volunteers, advancing towards a Phase 2a trial for chemotherapy-induced peripheral neuropathy. The data indicates safety and tolerability, paving the way for future FDA submissions and potential treatments for this condition.